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บทคดัยอ่  
วตัถปุระสงค์: เพื่อศกึษา 1) อตัราการควบคุมอาการชกั และ 2) ความสมัพนัธ์
ระหว่างขนาดยาฟีไนโทอนิกบัระดบัความเขม้ขน้ในซรีมัของผูป่้วยเดก็โรคลมชกั
ชาวไทย วิธีการศึกษา: การวจิยัแบบยอ้นหลงัไดค้ดัขอ้มลูจากเวชระเบยีนของคนไข้
เดก็โรคลมชกัทีร่กัษาทีโ่รงพยาบาลราชบุร ีในช่วง 1 ตุลาคม 2557 ถงึ 30 สงิหาคม 
2560 สาํหรบัวตัถุประสงคท์ี ่1 ผูป่้วยตอ้งใชย้าฟีไนโทอนิอย่างเดยีวในขนาดใดกไ็ด ้
ส่วนวตัถุประสงค์ที่ 2 ผู้ป่วยต้องใช้ยาขนาดที่แนะนําคือ 5 – 8 มก./กก./วนั การ
ควบคุมอาการชกัได้หมายถึง การปราศจากอาการชกัอย่างน้อย 6 เดือนต่อเน่ือง  
ความเขม้ขน้ในซีรมัที่อยู่ในช่วงรกัษา คือ 10 – 20 ไมโครกรมั/มิลลิลิตร ทดสอบ
ความสมัพนัธ์ระหว่างขนาดยาต่อวนักบัความเขม้ขน้ของยาในซรีมัโดยสหสมัพนัธ์
ของเพยีรส์นั ผลการศึกษา: ในผูป่้วย 84 ราย พบอตัราการควบคุมอาการชกัได้
ร้อยละ 86.90 ในผู้ป่วย 57 รายที่ควบคุมได้และใช้ยาในขนาดที่แนะนํา พบว่า
ขนาดยาต่อวนัสมัพนัธท์างบวกกบัความเขม้ขน้ในซรีมัอยา่งมนีัยสาํคญัทางสถติ ิ(r 
= 0.411; P-value = 0.002) สรปุ: พบอตัราการควบคุมอาการชกัไดใ้นระดบัสงูใน
ผูป่้วยเดก็โรคลมชกัชาวไทย และขนาดยาต่อวนัสมัพนัธท์างบวกกบัความเขม้ขน้
ในซรีมัอยา่งมนียัสาํคญัทางสถติ ิ 
คาํสาํคญั: ยาฟีไนโทอนิ, การควบคมุอาการชกั, ขนาดยาต่อวนั, ระดบัยาในซรีมั  
 
 
 
 
Abstract 
Objective: To examine 1) seizure control rate and 2) the association 
between daily dose of phenytoin and its serum concentration in Thai pediatric 
patients who took phenytoin monotherapy. Method: In this retrospective 
study, medical records of pediatric epileptic patients of Ratchaburi Hospital, 
Thailand, from October 1, 2014 to August 30, 2017 were examined. To 
estimate seizure control rate, the patients had to use phenytoin monotherapy 
regardless of daily dose. For the 2nd study objective, the patients also had to 
use the recommended dose of 5 – 8 mg/kg/day. Seizure control was defined 
as having no seizures for a continuous period of 6 months or longer. Serum 
phenytoin concentration of 10 – 20 mcg/ml was defined as within therapeutic 
level. Association of phenytoin daily dose with its serum concentration was 
tested for correlation using Pearson’s product moment correlation analysis. 
Results: Of 84 participants with phenytoin monotherapy, seizure control rate 
was 86.90%. Among 57 participants with seizure control and the 
recommended daily dose, daily doses of phenytoin were significantly, 
positively correlated with serum concentrations (r = 0.411; P-value = 0.002). 
Conclusion: Seizure control rate among Thai pediatric epileptic patients 
using phenytoin monotherapy was relatively high. Daily dose was significantly 
positively correlated with serum concentration.  
Keywords: phenytoin, seizure control, daily dose, serum concentration  
 
 
Introduction 
Phenytoin is a widely used antiepileptic drug (AEDs) in 
Thailand since it is relatively less costly compared with new 
AEDs. Phenytoin is expected for a long future use since it has 
been included in the National List of Essential Medicine of 
Thailand.1-3 However, problems of phenytoin use have been 
existing and not fully understood or solved. The dose of 
phenytoin in pediatric patients according to the Clinical 
Practice Guidelines for Epilepsy is 5 - 8 mg/kg/day. 1,2 
According to our clinical practice experience at Ratchaburi 
Hospital, despite the appropriate dose of phenytoin prescribed 
by the physician, serum phenytoin concentrations of phenytoin 
in some patients were still below the desirable therapeutic 
range of 10 - 20 mcg/ml.4-7 Whether efficacy and safety of 
phenytoin is related with its serum concentration has not been 
definitely concluded.  
In daily practice, predicting phenytoin serum concentration 
after dose adjustment had not been optimal. Therefore, the 
correlation between phenytoin daily dose and its serum 
concentration could offer certain confidence for practitioners, 
especially among pediatric patients. In addition, phenytoin 
efficacy as the seizure control rate in pediatric patients has 
not been well known. In a report of the World Health 
Organization in 2006, phenytoin use was associated with a 
response rate up to 70% of epileptic patients in all age 
groups.8 In Thai healthcare context, little has been known 
about its efficacy and safety in Thai pediatric patients; the care 
for these pateints could thus be suboptimal.  
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Based on the scarcity of information regarding the serum 
phenytoin concentration with respect to its daily dose among 
Thai pediatric epileptic patients, there has been a need to 
investgate such relationship to help improve epilepsy care. In 
addtition, the rate of seizure control among these Thai 
pediatric patients has not been reported. Such information 
was needed as the basis of effectiveness and for the 
improvement of epilepsy care for these patients.  Specifically, 
this present study aimed to examine 1) seizure control rate 
among pediatric epileptic patients using phenytoin 
monotherapy and 2) the association between daily dose of 
phenytoin and its serum concentration in pediatric patients 
who took phenytoin monotherapy with the recommended and 
widely used dose of 5 – 8 mg/kg/day and had epilepsy under 
control in real-life practice.  
  
Methods 
 
In this retrospective study, the seizure control rate (study 
objective 1) and the association between daily dose of 
phenytoin and its serum concentration (study objective 2) in 
pediatric epileptic patients were examined. The study 
population for determining the rate of seizure control among 
phenytoin monotherapy was pediatric epilepsy patients taking 
only phenytoin for their seizure. For the evaluation of the 
association between phenytoin daily dose and its serum 
concentration (2nd objective), the study population was 
pediatric epilepsy patients taking only phenytoin with the dose 
of 5 – 8 mg/kg/day according to Thai clinical practice 
guidelines for epilepsy1,2 and had their epilepsy under control. 
The reason for including only those with seizure control was 
that those with poor seizure would need the change of AED 
regimen change.  
The study sample for determining the rate of seizure 
control among phenytoin monotherapy was pediatric epilepsy 
patients who received only phenytoin for epilepsy treatment 
(monotherapy) from the pediatric neurological clinic of 
Ratchaburi Hospital from October 1, 2014 to August 30, 2017. 
These patients were diagnosed with epilepsy by a pediatric 
neurologist in accordance with the diagnostic criteria of the 
International League Against Epilepsy (ILAE) 2010.1,2 To be 
eligible, the patients had to take phenytoin either Dilantin 
Infatabs® or any extended release capsule. The study sample 
for evaluating of the association between phenytoin daily dose 
and its serum concentration was similar to that for determining 
seizure control rate and took the dose of 5 – 8 mg/kg/day 
phenytoin with their epilepsy under control.  
In terms of exclusion, the researcher excluded patients 
taking any drugs with potential interaction with phenytoin 
which could affect serum phenytoin concentration. Drugs 
which could increase phenytoin effects and/or serum 
concentrations included benzodiazepines, valproic acid9 and 
methylphenidate10; while drugs which could decrease 
phenytoin effects and/or serum concentrations were 
barbiturates, and carbamazepine.9 The researcher also 
excluded patients who stopped or skipped at least one day of 
phenytoin dosing, had allergic reaction to phenytoin, had their 
AED dosage regimen changed, had other AED concomitantly 
with phenytoin, missed at least one follow-up visit, were 
transferred for epileptic care at other healthcare setting, or 
stopped receiving epilepsy care at Ratchaburi Hospital during 
study period. In addition, patients with abnormalities in their 
liver and/or kidney functions as diagnosed by the physician 
and/or indicated by laboratory tests were also excluded.  
A serum phenytoin concentration for statistical analysis 
was chosen from the visit that seizure control was found after 
phenytoin dose adjustment. All serum phenytoin 
concentrations were at steady state. This was because the 
measure of phenytoin serum concentration was done at least 
14 – 20 days after the start or adjustment of the dose which 
allowed the drug to reach its steady state.1,2 The phenytoin 
serum concentration examination at Ratchaburi Hospital was 
analyzed by an automatic immunological analysis tool called 
ARCHITECT i2000SR.11 Based on literature review and actual 
practice, therapeutic level of phenytoin serum concentration 
ranges from 10 to 20 mcg/ml. 4-7  
Seizure control was defined as “well controlled” or “not 
well controlled” as stated by the pediatric neurologist in 
medical records. In epilepsy clinic of Ratchaburi Hospital, 
seizure control was guided by the frequency, duration and 
severity of seizures.1,2 Practically, having no seizures for a 
continuous period of 6 months or longer was considered “well 
controlled.” With multidisciplinary team approach of 
Ratchaburi Hospital, the evaluation on seizure control was 
usually carried out based on the diagnosis and assessment of 
the pediatric neurologist, together with the monitoring and 
evaluation by a pharmacist. The information about seizure 
control in the pediatric neurology clinic at Ratchaburi Hospital 
was highly adequate since two specialists spent a thorough 
examination with at least 10 to 15 minutes for each case and 
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multidisciplinary approach especially by pharmacist 
intervention could facilitate such comprehensive care and 
documentation.  
In terms of adverse events, data of adverse drug reactions 
(ADRs) in the medical records among the patients with 5 – 8 
mg/kg/day of phenytoin dose were extracted. ADRs associating 
with phenytoin verified by Naranjo's algorithm Thai version12 
as stated in medical records were eligible for study analysis.  
 
Ethical protection  
This retrospective study was approved by the Ethics 
Committee of Ratchaburi Hospital (approval number: COA-
RBHEC 013/2018). Data of the sampled patients were kept 
confidential. Only assigned patient numbers, instead of their 
actual name and hospital identification number, were used. 
 
Data analysis  
Demographic and clinical status data were presented as 
frequency with percentage. Phenytoin serum concentration 
was presented as mean with standard deviation. Phenytoin 
dose in relation to serum phenytoin concentration categories 
(sub-, within, and supra-therapeutic levels) were presented. 
The use of Pearson’s product moment correlation analysis to 
examine the association between daily phenytoin dose and its 
serum concentration was appropriate since the related 
assumptions for such analysis ADRs in relation to serum 
phenytoin concentration categories (sub-, within, and supra-
therapeutic levels) werer also detailed. Significance level for 
this statistical analysis was set at a 5% type I error (or P-value 
< 0.05).  
  
Results  
    
Of the total of 185 epileptic pediatric patients with 
phenytoin monotherapy, 84 of them were eligible for the first 
objective of the study (rate of seizure control). For 101 patients 
excluded, the reasons for their exclusion were: mild skin 
allergy (17 or 16.83%), incomplete follow-up (24 or 27.72%), 
receiving drugs with potential interaction with phenytoin (8 or 
7.92%), referral for healthcare settings close to their residence 
(18 or 17.82%), poor compliance with phenytoin regimen (14 
or 13.86%), and poor compliance of their parents with 
phenytoin dosing (16 or 15.85%).  
Of the 84 participants eligible for the first objective of the 
study (rate of seizure control), there were slightly more male 
than female patients (57.14% and 42.86%, respectively) 
(Table 1). The majoprity was in their 7 – 12 years of age 
(48.81%), followed by those in their 3 – 6 years (35.71%), and 
13 – 15 years (15.48%). Being located in the Ratchaburi 
province, the majority of the participants at the clinic of 
Ratchaburi Hospital was the residents of Ratchaburi (51.19%) 
rather than those from other provinces under the supervision 
of regional health service 5. In terms of insurance payment 
scheme, most of them were covered by the Universal 
Coverage scheme (85.70%). Almost all of them had no other 
illness or comorbid disease (94.05%) and no drug allergy 
(94.05%). All of them had no family history of epilepsy and 
three-quarters (75.00%) had partial seizure treated with 
phenytoin while the rest 25.00% had generalized tonic-clonic 
seizure (Table 1).    
 
 Table 1  Demographic and clinical characteristics of the 
participants (N = 84).  
Characteristics N % 
Gender   
Male 48 57.14 
Female 36 42.86 
Age ( year)   
3 - 6       30 35.71 
7 - 12     41 48.81 
13 - 15  13 15.48 
Residential province   
Ratchaburi 43 51.19 
Kanchanaburi 11 13.10 
Nakhon Pathom 8 9.50 
Phetchaburi 10 11.91 
Prachuap Khiri Khan 4 4.76 
Suphan Buri 5 5.95 
Samut Songkhram 2 2.38 
Samut Sakhon 1 1.19 
Payment scheme    
Universal Coverage  72 85.70 
Disability card  5 5.95 
Out-of-pocket 2 2.38 
Civil Servant Medical Benefit Scheme and other related schemes 5 5.95 
Other illnesses or comorbid diseases    
No 79 94.05 
Yes 5 5.95 
Allergy 2 40.00 
G6PD deficiency 2 40.00 
Thalassemia 1 20.00 
Drug allergy history   
No  79 94.05 
Yes   
Amoxicil lin 2 40.00 
Phenobarbital 2 40.00 
Ceftriaxone 1 20.00 
Family history of epilepsy 
No history 84 100 
Types of seizure treated with phenytoin 
Partial seizure 63 75.00 
Generalized tonic-clonic seizure  21 25.00 
 
Rate of seizure control 
Of these 84 participants who took phenytoin monotherapy 
regardless of the daily dose, 73 patients (86.90%) were able 
to control the seizure while 11 (13.10%) were not. Among 11 
ไทยเภสชัศาสตรแ์ละวทิยาการสขุภาพ ปี 15 ฉบับ 2, เมย. – มยิ. 2563 127 Thai Pharm Health Sci J Vol. 15 No. 2, Apr. – Jun. 2020 
participants with no seizure control, 7 of them (63.64%) had 
their phenytoin changed to other AED(s) and 4 (36.36%) used 
phenytoin concomitantly with other AED(s).  
Regarding of type of seizure, among those 73 patients with 
seizure control, 53 of them (72.60%) had partial seizure while 
the rest (20 or 27.40%) had generalized tonic-clonic seizure. 
Among 11 with no seizure control, most of them (10 or 
90.91%) had partial seizure while only 1 (9.09%) had 
generalized tonic-clonic seizure.  
 
Association between phenytoin daily dose and its serum 
concentration among patienst with seizure control  
Among 73 participants with seizure control, 69 of them 
(94.52%) were monitored for phenytoin serum concentration; 
while 4 patients (5.48%) were not. Among 69 participants with 
phenytoin serum concentration measured, the majority (57 or 
82.61%) used phenytoin at the recommended dose of 5 – 8 
mg/kg/day with an average dose of 6.63 ± 0.83 mg/kg/day 
(range: 5.00 – 8.00) and an average serum phenytoin 
concentration of 9.41 ± 3.98 mcg/ml (range: 4.23 – 19.05). 
Most of serum phenytoin concentrations were in sub-
therapeutic range (64.91%), followed by those within 
therapeutic range (35.09%) (Table 2).  
 
 Table 2  Phenytoin dose and serum drug concentration 
measured in 69 patients.  
Dosage 
(mg/kg/day) N (%) 
Average dose* 
(range) 
Average serum 
conc.# (range) 
N ( %) by therapeutic range† 
Sub-therapeutic 
range 
Within therapeutic 
range 
< 5 7 (10.14) 4.49 ± 0.36    
(4.00 - 4.93) 
10.83 ± 3.90  
(3.60 - 15.12) 
2 (28.57)  5 (71.43) 
5 - 8 57 (82.61)  6.63 ± 0.83  
(5.00 - 8.00) 
9.41 ± 3.98   
(4.23 - 19.05) 
37 (64.91)  20 (35.09) 
> 8 5 (7.25) 8.45 ± 0.25  
(8.11 - 8.70) 
8.21 ± 2.95  
(4.82 - 11.33) 
3 (60.00) 2 (40.00) 
Total 69 (100)   42 (60.87) 27 (39.13) 
  * mg/kg/day presented as mean ± standard deviation.   
  # concentration (mcg/ml) presented as mean ± standard deviation.   
  † Target therapeutic range: 10 - 20 mcg/ml. 
  
It was found that there was a significant relationship 
between the daily dose of phenytoin and its serum 
concentration. Among 57 participants receiving the 
recommended phenytoin dose of 5 – 8 mg/kg/day, their actual 
daily doses of phenytoin were positively correlated with their 
serum phenytoin concentrations (r = 0.411) with a statistical 
significance (P-value = 0.002).  
In addition, among these 57 participants with seizure 
control and the daily dose of 5 – 8 mg/kg/day, there were 39 
patients (68.42%) with partial seizure and 18 (31.58%) with 
generalized tonic-clonic seizure. Among 39 patients with 
partial seizure, there were 27 (69.23%) with sub-therapeutic 
level and 12 (30.77%) within therapeutic level; while 10 
(55.56%) with sub-therapeutic level and 8 (44.44%) with within 
therapeutic level were found in 18 patients with generalized 
tonic-clonic seizure.   
 
Adverse drug reactions  
Among 57 participants receiving 5 – 8 mg/kg/day 
phenytoin dose, 9 of them experienced adverse drug reactions 
(ADRs) (Table 3). The most frequently found ADR was 
gingival hypertrophy (5 participants or 55.56%), followed by 
dizziness (3 or 33.33%) and nausea (1 or 11.11%). Among 
these 9 participants experiencing ADRs, 5 (or 55.56%) had 
their phenytoin serum concentrations within therapeutic range 
of 10 – 20 mcg/ml; while the rest 4 participants were sub-
therapeutic.   
 
 Table 3  Adverse drug reactions, daily dose, serum 
phenytoin concentrations, and therapeutic levels among 9 of 57 
patients with 5 – 8 mg/kg/day of phenytoin dose.  
Adverse 
drug 
reactions 
Dosage 
(mg/kg/day) 
Serum  
phenytoin conc.  
(mcg/ml) 
Therapeutic level N % 
Gingival  
hypertrophy 
6.25 9.61 Sub-therapeutic 1  
7.61 14.53 Within therapeutic 1  
7.50 18.03 Within therapeutic 1  
5.76 5.26 Sub-therapeutic 1  
6.10 10.37 Within therapeutic 1  
Total   5 55.56 
Nausea 6.51 16.32 Within therapeutic 1  
Total    1 11.11 
Dizziness 6.67 8.81 Sub-therapeutic 1  
5.36 11.97 Within therapeutic 1  
5.55 7.65 Sub-therapeutic 1  
Total    3 33.33 
Total 9 100 
 
 
Discussions and Conclusion 
In this retrospective study examing seizure control rate 
among 84 pediatric epileptic patients taking phenytoin 
monotherapy regardless of the daily dose, the seizure control 
rate of 86.90% was found. Since there has been no studies 
reporting seizure control rate among pediatric patients, it 
would be difficult to conclude how successful of phenytoin 
monotherapy in Thai pediatric patients was. However, based 
on the report of the World Health Organization in 2006 stating 
that phenytoin use was associated with a response rate up to 
70% of epileptic patients in all age groups8, the 86.90% control 
rate in our study suggested a somewhat successful care. This 
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could be attributable to the fact that epilepsy care at the 
pediatric neurology clinic at Ratchaburi Hospital used a 
multidisciplinary care approach where physicians and 
pharmacists took part in comprehensive evaluations of 
efficacy and safety of the therapy and the dosage regimen 
adjustment using all available tools including serum drug 
concentration.   
Among 57 participants with phenytoin monotherapy with 
the recommended dose of 5 – 8 mg/kg/day, almost two-thirds 
had their serum phenytoin concentrations in subtherapeutic 
range (64.91%) while the rest (35.09%) were within 
therapeutic range (10 – 20 mcg/ml). This was surprising since 
a relative large number of the participants had their seizure 
under control. Their average daily dose (6.63 ± 0.83 
mg/kg/day) was in the middle of the recommended dose of 5 
– 8 mg/kg/day. This suggested that their dose of phenytoin 
could be increased relatively safely close to the upper limit (8 
mg/kg/day) to reach the therapeutic level.  
The finding that there was a significant, positive correlation 
between daily dose of phenytoin and its serum concentration 
(r = 0.411, P-value = 0.002) could help practitioners relatively 
more convinced to adjust the dose. However, this moderate 
correlation has certain level of limitation in practical use. A 
beta coefficient from regression could be more useful in 
deciding the increased dose for specific target serum 
concentration. More future studies with a larger sampel size 
should be conducted to determine the extent of the 
association. 
Additional analysis showed that among 84 participants 
with phenytoin monotherapy, 10 of 11 participants (90.91%) 
who had no seizure control and 53 of 73 participants (72.60%) 
who had seizure control were patients with partial seizure. 
This finding suggested a lower seizure control rate among 
patients with partial seizure. This discrepancy could be of 
interest for future research to examine for its significance. If 
significant, it should alarm ways to improve the care for 
patients with partial seizure.  
Another additional analysis on 57 participants with seizure 
control and the daily dose of 5 – 8 mg/kg/day showed almost 
no discrepancy regarding chance of having sub-therapeutic 
level between patiens with partial seizure and with generalized 
tonic-clonic seizure. Among 39 patients with partial seizure, 
there were 27 patients (69.23%) with sub-therapeutic level 
and 12 (30.77%) within therapeutic level. However, patients 
with generalized tonic-clonic seizure seemed to have a lower 
proportion of having sub-therapeutic level (10 of 18, or 
55.56%). It has been inclonclusive about the relationship of 
type of seizure with either serum phenytoin concentration or 
clinical response as shown in a study with small sample size.13 
This relationship of type of seizure with either serum phenytoin 
concentration or clinical response, if any, could help improve 
the care and prompt future research.  
In terms of adverse drug reactions, gingival hypertrophy, 
nausea and dizziness were found in 5, 1 and 3 patients with 
seizure and the recommended dose of 5 – 8 mg/kg/day, 
respectively. The incidence of gingival hypertrophy deemed 
somewhat alarming and should prompt a more comprehensive 
investigation. Our findings were consistent with the fact that 
these three adverse drug reactions were independent of daiy 
dose and serum concentration of phenytoin since patients with 
sub-therapeutic level also experienced the reactions.  
This present study has certain limitations. With a relatively 
small sample, our findings could have a lower power of 
analysis. Future studies with a larger sample size are needed. 
To achiebe a better generalization to all Thai pediatric epileptic 
patients, studies with multi-centers are encouraged.  
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